Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction)
Why the study?
Is cardiac resynchronization therapy cost-effective compared with optimal medical therapy in patients with asymptomatic to mild heart failure?
Population
262 patients with New York Heart Association II heart failure or NYHA I with previous HF symptoms, QRS ≥ 120…
Comparison
Cardiac resynchronization therapy (CRT-ON) vs Optimal medical therapy (CRT-OFF)
Design
Other
Follow-up
10 year time period (modeled)
Authors
Discussion
Loading...
Member takes
Implication
Supports CRT in asymptomatic/mild HF; extends cost-effectiveness evidence to reinforce guideline-directed use.
Structured PICO
Is cardiac resynchronization therapy cost-effective compared with optimal medical therapy in patients with asymptomatic to mild heart failure?
P
Population
262 patients with New York Heart Association (NYHA) II heart failure (HF) or NYHA I with previous HF symptoms, QRS ≥ 120 ms, left ventricular ejection fraction ≤ 40% (European cohort of the REVERSE clinical trial)
I
Intervention
Cardiac resynchronization therapy (CRT-ON)
C
Comparator
Optimal medical therapy (CRT-OFF)
O
Outcome
Incremental cost-effectiveness ratio (costs, life years and quality-adjusted life years) over a 10 year time period
Cardiac resynchronization therapy is a cost-effective intervention for patients with mildly symptomatic or asymptomatic heart failure with previous symptoms and left ventricular dysfunction.
Cite This Study
Linde et al. (2010) studied this question.